Porphyromonas uenonis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Porphyromonas uenonis is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 7 gut microbiome compilation studies or metastudies. The DNA G+C content is 52.5%. Porphyromonas uenonis is probably a common, although minor, coloniser of the gut. (Finegold2004a; Summanen2010Bergey)



  • This organism has been recovered from clinical sources (infection, ulcer, abscess - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Finegold2004a); (Summanen2010Bergey);
    Character Response
  • 💧
  • Bile tolerance:
  • Doesn't tolerate bile
  • 🌡
  • Temperature tolerance:
  • Grows optimally at 37℃.
  • Active enzymes:
  • Ala arylamidase; alkaline phosphatase; acid phosphatase; esterase C4; esterase lipase C8; Leu-Gly arylamidase;
    • SPECIAL FEATURES (Finegold2004a); (Summanen2010Bergey);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; propionate; butyrate; succinate; isovalerate; indole;
  • Haemolysis:
  • beta (weak)
  • ✗
  • Nitrate:
  • not reduced
  • Pigments:
  • black
    • RESPONSE TO ANTIBIOTICS (Finegold2004a); (Summanen2010Bergey); (Goldstein2018a); (Goldstein2013b); (Citron2012a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; imipenem; meropenem; piperacillin-tazobactam; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefoxitin; ceftizoxime;
  • Macrolides:
  • fidaxomicin;
  • Tetracyclines:
  • tigecycline;
  • Quinolines:
  • gemifloxacin; moxifloxacin; trovafloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;

  • Finegold, Sydney M., Lawson, P. A., Vaisanen, M.-L., Molitoris, D. R., Song, Y., Liu, C., & Collins, M. D. (2004). Anaerofustis stercorihominis gen. nov., sp. nov., from human feces. Anaerobe, 10(1), 41–45.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Bacteroidetes Class:  Bacteroidia Order:  Bacteroidales Family:  Porphyromonadaceae Genus:  Porphyromonas Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod Pigment:  black
    Health:  Unknown
    Source:  clinical sources (infection, ulcer, abscess - CCUG) and human faeces
    DNA G+C(%):  52.5
    Opt. T:  37℃
    Bile reaction(%):  neg
    		Aesculin:  neg Urea:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Mannose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Glucose:  neg Lactose:  neg Inositol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg ArgDH:  neg Chymotrypsin:  neg GluDC:  neg Trypsin:  neg AlanineAA:  + GluGluAA:  vr GlyAA:  neg LeuAA:  vr LeuGlyAA:  + PyrrolidAA:  neg AlkalineP:  + AcidP:  + Esterase(C4):  + EstLip(C8):  + Lipase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Propionate:  + Butyrate:  + Succinate:  + Isovalerate:  + Indole:  + Pigment:  black
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(<1)
    ampicillin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–2)
    amp-sulb:  S(MIC50): 0.06, MIC90: 1, RNG: (0.06–2)
    piper-taz:  S(MIC50): 0.015, MIC90: 0.015, RNG: (0.015–0.03)
    tica-clav:  S(<1)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.015–0.125)
    meropenem:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.125)
    cefoxitin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–2)
    ceftazidime:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.25–32)
    ceftizoxime:  S(<1)
    fidaxomicin:  R(MIC50): >32, MIC90: >32, RNG: (2–>32)
    gemifloxacin:  S(<1)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.03–16)
    trovafloxacin:  S(<1)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tigecycline:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.5)
    vancomycin:  S(MIC50): 2, MIC90: 2, RNG: (0.5–4)
    metronidazole:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.03–1)
    clindamycin:  S(MIC50): 0.06, MIC90: 1, RNG: (0.06–>128)

    References

    SPECIFIC REFERENCES FOR PORPHYROMONAS UENONIS
  • Finegold2004a - Porphyromonas uenonis sp. nov., a Pathogen for Humans Distinct from P. asaccharolytica and P. endodontalis.
  • Summanen2010Bergey - Bergey's manual of systematic bacteriology. Vol. 4, The Fusobacteria. Family Porphyromonadaceae, Genus I. Porphyromonas
  • Yachida2019 - Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Goldstein2013b - Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PORPHYROMONAS UENONIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021